Dear Editor,
We present the case of an 82-year-old Caucasian female who was evaluated in 2009 with an 18-month history of purulent nailbeds of the bilateral great toes and thumbs. She reported a history of hypertension, non-insulin-dependent diabetes mellitus (NIDDM), and pernicious anaemia. She denied recurrent fevers, arthritis, or a family history of pustular psoriasis. Her medications included lisinopril, frusemide, potassium, and metformin. She reported allergies to codeine and erythromycin, and no new medications in the past 3 months. Previous biopsies for H&E and 180 Clinical presentation at the time of referral is shown in Figure  1 . Adalimumab was commenced (40 mg subcutaneously every fortnight) on a compassionate use basis for a 12-week trial ( Table 1 ). Limb plaques improved, however, the thumb remained recalcitrant and new pustules appeared by week 8 of therapy. Thioguanine 40 mg b.i.d. was trialled for 4 weeks; however, due to further deterioration, the patient requested resumption of cyclosporine at 300 mg/day. Worsening hypertension along with creatinine elevation necessitated cessation of cyclosporine and replacement with oral methotrexate and prednisolone whilst awaiting application for compassionate use of ustekinumab. Three doses of ustekinumab 45 mg were approved with minimal improvement (PASI score 16). Cyclosporine 100 mg b.i.d. was subsequently restarted with no impact upon nail disease. Blood pressure and eGFR remained within the normal range. Adjuvant topical therapies included miconazole 2% solution, calcipotriol/ betamethasone dipropionate ointment, and saturated solution of potassium iodide. No repeat isolation of M. fortuitum was identified during the period of treatment. Thalidomide was commenced at 50 mg b.i.d. with moderate improvement of nail symptoms, unfortunately treatment was discontinued due to cost. A significant flare (PASI score 27) resulted in resumption of cyclosporine and application for infliximab. Worsening mobility meant that regular attendance for infusions was impractical. Combined ustekinumab 45 mg, cyclosporine 200 mg b.i.d., and prednisone 7.5 mg/day commenced in July 2011 with rapid improvement (PASI score 2.7 at 4 weeks) but resistant nail disease. After 12 months, 2 infusions of intravenous immunoglobulin 0.4 mg/kg were administered, with no benefit to the nails. The patient was lost to follow-up and passed away after an intracranial haemorrhage, still on cyclosporine.
Discussion
ACH is a chronic, recalcitrant disease with a predisposition to elderly females [1] , is considered an acral variant of pustular psoriasis [2] , and shares a common pathogenesis with DITRA (deficiency in interleukin-1 receptor antagonist) [2] [3] [4] . Physicians unfamiliar with the disease can misdiagnose it as a chronic infection through identification of commensals (such as M. fortuitum ) on culture specimens. Reports of a Lebanese family with a common 181 IL-36RN mutation presenting as both ACH and GPP raises questions as to the epigenetic or environmental cues that may result in different phenotypes [2] , progression from one to the other [5] , or manifestations of both, as seen in our case. It is also unclear why, if the conditions are related, such contrasting responses to treatment are seen within the same individual and why long-term remission often remains elusive [6] . While secondary infection of the nailbed can occur in ACH, it is not known to contribute to the activity of disease. The use of biologic agents is variable in efficacy [6] with the IL-1 antagonists Anakinra and Gevokizumab [4] , as well as the IL-17 antagonists Secukinumab and Ixekizumab [7] showing future potential.
